Earendil Labs, an expert in AI-driven research and development of next-generation biologics therapeutics, and Sanofi have entered into a license agreement for two potential first-in-class bispecific antibodies in the field of autoimmune and inflammatory bowel diseases.

Under the agreement, Sanofi will obtain exclusive worldwide rights to two bispecific antibodies, HXN-1002 and HXN-1003, both utilizing Earendil Labs’ proprietary AI and high-throughput discovery & research platform.

As part of the agreement:

• Earendil Labs will receive an upfront payment of $125 million.
• Earendil Labs is eligible to receive up to a total of $1.72 billion in development and commercial milestone payments, including a $50 million near-term payment.
• Earendil Labs is eligible to receive tiered royalties on product sales ranging from the high-single to low-double digits.

“We are thrilled to collaborate with Sanofi, a global leader in immunology, to advance the development of two bispecifics, HXN-1002 and HXN-1003, for autoimmune and inflammatory bowel diseases,” said Jian Peng, PhD, CEO of Earendil Labs, “Our platform leverages state-of-the-art predictive protein modeling and high-throughput biology, revolutionizing the discovery and development of bispecific antibodies. This collaboration underscores Earendil Labs’ capability to generate potential first-in-class or best-in-class product candidates, with the aim of transforming patient care.”

Zhenping Zhu, MD, PhD, President & co-CEO of Earendil Labs, added: “We firmly believe that Sanofi’s extensive expertise in the autoimmune disease field will significantly accelerate the development of HXN-1002 and HXN-1003, ultimately bringing these potentially life-changing treatments to patients worldwide as soon as possible.”